Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

3 Small-Cap Stocks Walking a Fine Line

March 30, 2026

Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment

March 10, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g...

Amneal’s 34% return over the past six months has outpaced the S&P 500 by 30.9%, and its stock price has climbed to $13.16 per share. This performance may hav...

Topics Artificial Intelligence Intellectual Property

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

March 10, 2026

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) Reports Q4 2025 Earnings Beat on Strong Profitability ↗

Topics Stocks

February 27, 2026

Via Chartmill

Topics Earnings

3 Value Stocks We’re Skeptical Of

March 05, 2026

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Amneal to Participate in Upcoming Investor Conference

March 05, 2026

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell 6.3% in the afternoon session after the company reported fourth-quarter results that beat expectations but provided a...

Why Amneal (AMRX) Stock Is Trading Lower Today

February 27, 2026

Amneal (AMRX) Q4 2025 Earnings Call Transcript

Amneal (AMRX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Via The Motley Fool

Topics Earnings

Amneal (NASDAQ:AMRX) Beats Q4 CY2025 Sales Expectations

February 27, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 11.5% year on year to $814.3 million. On the other hand,...

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

February 27, 2026

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know.

Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow

February 25, 2026

In a seismic shift for global trade and constitutional law, the Supreme Court of the United States ruled on February 20, 2026, that the executive branch lacks the authority to unilaterally impose...

Topics Artificial Intelligence

Supreme Court Strikes Down IEEPA Tariffs, Mandating Billions in Immediate Rebates

February 24, 2026

Via MarketMinute

Topics Bonds Economy Government

3 Russell 2000 Stocks We Find Risky

February 12, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

3 Small-Cap Stocks That Fall Short

February 04, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

3 Cash-Producing Stocks That Concern Us

February 01, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also...

3 Healthcare Stocks We Steer Clear Of

January 29, 2026

Topics Stocks

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

January 28, 2026

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

January 27, 2026

Amneal has been on fire lately. In the past six months alone, the company’s stock price has rocketed 63.3%, reaching $13.34 per share. This was partly thanks to its solid quarterly results, and the...

2 Reasons to Sell AMRX and 1 Stock to Buy Instead

January 25, 2026

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

December 22, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

1 Small-Cap Stock to Target This Week and 2 That Underwhelm

December 17, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

December 09, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

December 05, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand,...

3 Healthcare Stocks We’re Skeptical Of

December 02, 2025

Represents second complex respiratory therapeutic product approval in Q4 2025

Topics Stocks

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

December 02, 2025

Amneal to Participate in Upcoming Investor Conferences

December 02, 2025

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

December 01, 2025

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares? ↗

November 28, 2025

The pharmaceutical company has experienced sales growth over the past five years.

Via The Motley Fool

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...